Thrombin biosimilar - Leukocare / Navigo Proteins

Drug Profile

Thrombin biosimilar - Leukocare / Navigo Proteins

Alternative Names: recombinant human thrombin - Navigo Proteins/LEUKOCARE; rhThrombin - Navigo Proteins/LEUKOCARE

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEUKOCARE; Scil Proteins
  • Developer Navigo Proteins
  • Class Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Thrombin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Haemorrhage

Highest Development Phases

  • No development reported Haemorrhage

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Haemorrhage in Germany (Topical)
  • 15 Nov 2013 Thrombin biosimilar - Leukocare / Scil Proteins is available for licensing as of 30 Oct 2013.
  • 30 Oct 2013 Clinical trials in Haemorrhage in Germany (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top